Skip to main content
. 2014 Nov 17;2014(11):CD008726. doi: 10.1002/14651858.CD008726.pub2

Comparison 14. Other antibiotic regimens (D to I) versus cephalosporins (B).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Maternal sepsis 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
1.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Maternal endometritis 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
2.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Beta‐lactams (F) versus cephalosporins (B) 1 48 Risk Ratio (M‐H, Fixed, 95% CI) 1.18 [0.08, 17.82]
3 Infant sepsis 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
3.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Infant oral thrush 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
4.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Maternal fever (febrile morbidity) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
5.1 Macrolides (E) versus cephalosporins (B) 1 70 Risk Ratio (M‐H, Fixed, 95% CI) 7.0 [0.37, 130.69]
5.2 Beta‐lactams (F) versus cephalosporins (B) 1 48 Risk Ratio (M‐H, Fixed, 95% CI) 0.59 [0.06, 6.09]
6 Maternal wound infection 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
6.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Beta‐lactams (F) versus cephalosporins (B) 1 48 Risk Ratio (M‐H, Fixed, 95% CI) 0.39 [0.02, 9.15]
7 Maternal urinary tract infection 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
7.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Beta‐lactams (F) versus cephalosporins (B) 1 48 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Maternal thrush 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
8.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Maternal composite serious infectious complication 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Maternal composite adverse effects 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Maternal allergic reactions 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
11.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Maternal nausea 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
12.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Maternal vomiting 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
13.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Maternal diarrhoea 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
14.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Maternal skin rash 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
15.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Immediate infant adverse effects 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
16.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Infant unsettled 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Infant diarrhoea 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
18.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Infant skin rash 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
19.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Development of bacterial resistance 0   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
20.1 Macrolides (E) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Maternal length of hospital stay 0   Mean Difference (IV, Fixed, 95% CI) Subtotals only
21.1 Macrolides (E) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Infant length of hospital stay 0   Mean Difference (IV, Fixed, 95% CI) Subtotals only
22.1 Macrolides (E) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Infant's immune system development 0   Mean Difference (IV, Fixed, 95% CI) Subtotals only
23.1 Macrolides (E) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 Infant general health 0   Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
24.1 Macrolides (E) versus cephalosporins (B) 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
25 Infant frequency of hospital visits 0   Mean Difference (IV, Fixed, 95% CI) Subtotals only
25.1 Macrolides (E) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
25.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26 Costs 0   Mean Difference (IV, Fixed, 95% CI) Subtotals only
26.1 Macrolides (E) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26.2 Beta‐lactams (F) versus cephalosporins (B) 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]